search
Back to results

Endoscopic Gastric Reduction for Weight Management

Primary Purpose

Obesity

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Botulinum toxin
Overstitch Endoscopic Suturing System
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obesity, Weight loss, Gastric reduction (volume), BMI 30-40

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Body Mass Index (BMI) between 30 and 40
  • Age >18 and ≤50
  • Stable weight for 3 months (within 5% of BMI)
  • Normal basic labs (CBC, chemistry profile, creatinine)
  • Negative pregnancy test for females >18 or ≤ 50

Exclusion Criteria:

  • Diabetes
  • Unstable coronary artery disease
  • Heart failure
  • Cardiac arrhythmia
  • Cardiac valvular disease
  • Obstructive of interstitial lung disease
  • Females of child-bearing age >18 or ≤ 50 who are pregnant or lactating
  • Mallampati score of 4
  • ASA 3 or above
  • Previous gastric surgery
  • Ulcer disease
  • Gastroparesis,
  • > 5 cm Hiatal hernia
  • Congenital anomalies of the GI tract
  • Currently on or prescribed a medication known to affect weight within 3 months of study entry.

Sites / Locations

  • Mayo Foundation

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Botulinum toxin at injection site

Arm Description

All subjects will have gastroplasty performed using the Overstitch Endoscopic Suturing System. Botulinum toxin will be injected in every other suture site in half of the randomly patients selected.

Outcomes

Primary Outcome Measures

Change from baseline Bariatric Quality of Life (BQL) Questionaire

Secondary Outcome Measures

Change from baseline Three factor Eating Questionnaire (TFEQ-R21)

Full Information

First Posted
August 27, 2012
Last Updated
April 6, 2015
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT01682733
Brief Title
Endoscopic Gastric Reduction for Weight Management
Official Title
Endoscopic Gastric Reduction for Weight Management: A Pilot Feasibility Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The proposed study is a prospective, pilot study to assess the feasibility of a novel endoscopic suturing system to reduce gastric volume by changing the shape of the stomach for the primary treatment of obesity. The investigators aim to recruit ten subjects with a body mass index between 30-40 for this study. Vertical sutures will be performed using the endoscopic suturing system to deploy 10-17 interrupted full thickness sutures. Botulinum toxin(approximately 30 units) will be injected around the sutures insertion sites in half of the subjects randomly to slow down muscular grinding of the stomach to see if it improves durability of the procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity, Weight loss, Gastric reduction (volume), BMI 30-40

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Botulinum toxin at injection site
Arm Type
Experimental
Arm Description
All subjects will have gastroplasty performed using the Overstitch Endoscopic Suturing System. Botulinum toxin will be injected in every other suture site in half of the randomly patients selected.
Intervention Type
Drug
Intervention Name(s)
Botulinum toxin
Other Intervention Name(s)
Botox
Intervention Description
In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
Intervention Type
Device
Intervention Name(s)
Overstitch Endoscopic Suturing System
Intervention Description
The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
Primary Outcome Measure Information:
Title
Change from baseline Bariatric Quality of Life (BQL) Questionaire
Time Frame
baseline to 3 months
Secondary Outcome Measure Information:
Title
Change from baseline Three factor Eating Questionnaire (TFEQ-R21)
Time Frame
baseline to 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Body Mass Index (BMI) between 30 and 40 Age >18 and ≤50 Stable weight for 3 months (within 5% of BMI) Normal basic labs (CBC, chemistry profile, creatinine) Negative pregnancy test for females >18 or ≤ 50 Exclusion Criteria: Diabetes Unstable coronary artery disease Heart failure Cardiac arrhythmia Cardiac valvular disease Obstructive of interstitial lung disease Females of child-bearing age >18 or ≤ 50 who are pregnant or lactating Mallampati score of 4 ASA 3 or above Previous gastric surgery Ulcer disease Gastroparesis, > 5 cm Hiatal hernia Congenital anomalies of the GI tract Currently on or prescribed a medication known to affect weight within 3 months of study entry.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Barham K AbuDayyeh, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Foundation
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
26748219
Citation
Abu Dayyeh BK, Acosta A, Camilleri M, Mundi MS, Rajan E, Topazian MD, Gostout CJ. Endoscopic Sleeve Gastroplasty Alters Gastric Physiology and Induces Loss of Body Weight in Obese Individuals. Clin Gastroenterol Hepatol. 2017 Jan;15(1):37-43.e1. doi: 10.1016/j.cgh.2015.12.030. Epub 2015 Dec 31.
Results Reference
derived

Learn more about this trial

Endoscopic Gastric Reduction for Weight Management

We'll reach out to this number within 24 hrs